Immunogenicity and safety of a bivalent (omicron BA.5 plus ancestral) SARS-CoV-2 recombinant spike protein vaccine as a heterologous booster dose: interim analysis of a phase 3, non-inferiority, randomised, clinical trial.

导出 LinkOut

翻译打印收藏纠错

作者： Chijioke,Bennett ^[1] ; Wayne,Woo ^[2] ; Mark,Bloch ^[3] ; King,Cheung ^[4] ; Paul,Griffin ^[5] ; Rahul,Mohan ^[6] ; Sachin,Deshmukh ^[7] ; Mark,Arya ^[8] ; Oscar,Cumming ^[9] ; A Munro,Neville ^[10] ; Toni G,McCallum Pardey ^[9] ; Joyce S,Plested ^[2] ; Shane,Cloney-Clark ^[2] ; Mingzhu,Zhu ^[2] ; Raj,Kalkeri ^[2] ; Nita,Patel ^[2] ; Alex,Marcheschi ^[2] ; Jennifer,Swan ^[2] ; Gale,Smith ^[2] ; Iksung,Cho ^[2] ; Gregory M,Glenn ^[2] ; Robert,Walker ^[2] ; Raburn M,Mallory ^[2] ; Novavax 2019nCoV-311 Study Group

作者单位： Novavax, Gaithersburg, MD, USA. Electronic address: cbennett@novavax.com. ^[1] Novavax, Gaithersburg, MD, USA. ^[2] Holdsworth House Medical Practice, Sydney, NSW, Australia; Kirby Institute, University of New South Wales, Sydney, NSW, Australia. ^[3] Emeritus Research, Camberwell, VIC, Australia. ^[4] Mater Health, Mater Medical Centre, South Brisbane, QLD, Australia; The University of Queensland, Mater Clinical Unit, Brisbane St Lucia, QLD, Australia. ^[5] Paratus Clinical Research Western Sydney, Blacktown, NSW, Australia. ^[6] Griffith University, Southport, QLD, Australia. ^[7] Australian Clinical Research Network, Maroubra, NSW, Australia. ^[8] Novatrials, Kotara, NSW, Australia. ^[9] AusTrials, Taringa, QLD, Australia. ^[10]